Alnylam Pharmaceuticals
ALNY
#801
Rank
A$44.92 B
Marketcap
A$335.76
Share price
1.51%
Change (1 day)
-50.85%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2026 (TTM): A$5.61

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is A$5.29. In 2025 the company made an earnings per share (EPS) of A$2.51.

EPS history for Alnylam Pharmaceuticals from 2012 to 2026

Annual EPS

Year EPS Change
2026 (TTM)A$5.61123.33%
2025A$2.51
2023A-$4.92-62%
2022A-$12.9629.03%
2021A-$10.04-3.36%
2020A-$10.39-8.48%
2019A-$11.367.67%
2018A-$10.5539.74%
2017A-$7.5512.94%
2016A-$6.6838.84%
2015A-$4.81-32.88%
2014A-$7.17259.44%
2013A-$1.99-31.25%
2012A-$2.90

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Novartis
NVS
A$9.79 85.22%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
A$3.57-32.46%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
A$59.33 1,022.16%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
A-$0.80-115.04%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
A-$1.02-119.26%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
A-$0.38-107.12%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
A$1.91-63.85%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
A$1.13-78.63%๐Ÿ‡บ๐Ÿ‡ธ USA